Promoting adherence to treatment for latent TB infection through mobile phone text messaging: study protocol for a pilot randomized controlled trial by Eyal Oren et al.
STUDY PROTOCOL Open Access
Promoting adherence to treatment for
latent TB infection through mobile phone
text messaging: study protocol for a pilot
randomized controlled trial
Eyal Oren1,4* , Melanie L. Bell1, Francisco Garcia2,3, Carlos Perez-Velez3 and Lynn B. Gerald2,4
Abstract
Background: An estimated two billion people, over one third of the world’s population, have latent infection with
Mycobacterium tuberculosis (LTBI). Patient adherence to LTBI treatment is currently poor given that individuals show
no symptoms of illness and may not feel that they are at risk of developing active tuberculosis (TB). Short text messages
can serve as a simple reminder to take medications and address barriers to adherence such as forgetfulness and lack of
social support.
Methods/design: We aim to determine the feasibility and acceptability of text reminders for improving adherence in
latent TB patients using a randomized controlled single-blinded trial, measuring adherence through an increase in
treatment completion rates. Forty adult LTBI participants will be randomized to either text messages plus phone call
reminders or phone call reminders only (usual care). Recruitment, retention, and study acceptability will be assessed as
primary outcomes.
Discussion: This pilot study will examine the feasibility of using text messaging for increasing adherence to treatment
for latent tuberculosis infection. The study will allow for evaluation of process measures and challenges and development
of a model for scaling up an effectiveness trial for increasing treatment adherence.
Trial registration: NCT02690818 (Clinical Trials.gov)
Keywords: Latent tuberculosis infection, Text messages, Treatment adherence
Background
Tuberculosis (TB) is a leading cause of death from an
infectious disease worldwide. An estimated two billion
people, one third of the world’s population, are infected
with Mycobacterium tuberculosis, resulting in approxi-
mately 1.4 million deaths annually [1]. People with un-
treated or undiagnosed TB who do not complete their
prescribed treatment regimen pose major health risks to
themselves and to the general population. Those patients
who do not adhere to treatment for active TB remain
infectious longer and are more likely to relapse and die.
They are also vulnerable to developing drug-resistant
tuberculosis [2].
Adherence to latent tuberculosis infection therapy
Approximately one third of individuals exposed to some-
one with active TB disease develop latent TB infection
(LTBI) [3]. Patients who develop LTBI are asymptomatic
and non-contagious but the overall lifetime risk of LTBI
progression to active TB is estimated at approximately
5–10% [4]. This risk is greatly increased among im-
munosuppressed individuals, including those with HIV,
diabetes, and heavy steroid use [5, 6]. The populations
with the highest burden of LTBI in the USA are primarily
from immigrant, refugee, and non-English speaking com-
munities. Ten million individuals in the USA, including
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19% of foreign-born residents, are estimated to have LTBI
[7, 8]. One approach to reduce the burden of TB is to de-
tect and treat persons while they still have LTBI to prevent
disease development. This approach is recommended for
individuals at increased risk for progression to disease [9].
These include persons who were born in countries with
increased tuberculosis prevalence and persons who live in
high-risk congregate settings. Patient adherence to LTBI
therapy is low as LTBI is asymptomatic, patients may not
understand risk of developing active TB, LTBI therapy has
potential side effects, and LTBI therapy is of long duration
(usually 9 months) [10–12]. In a large prospective North
American study, lower treatment completion rates were
noted among females, US-born, Hispanic, and uninsured
populations [13]. As a result, the proportion of persons
who complete LTBI treatment in the USA ranges between
39 and 65%. These low adherence rates undermine the po-
tential benefits of preventing TB progression in individuals
with LTBI and maximizing TB control from a public
health standpoint [14, 15]. Low adherence also increases
the burden of active TB disease within the community
and can increase the rate of drug-resistant TB strains.
One of the major shortcomings in TB control thus re-
mains the difficulty in reaching marginalized populations
for the purpose of TB prevention [16]. The ability to fol-
low treatment plans in an optimal manner is frequently
compromised by multiple barriers. Others have noted
some of these barriers, including younger age, lower per-
ceived risk for TB disease, and self-administered regi-
mens [17]. Measures to improve adherence aim to (1)
help patients address social issues which may hinder
their ability to follow treatment, (2) enhance contact
with health professionals, and (3) strengthen communi-
cation between health professionals and patients during
treatment [18]. The best way to improve adherence to
long-term treatment regimens may be through extended
supervision of patients [19]. However, direct supervision
of treatment is expensive and has mixed results in in-
creasing LTBI treatment completion [20, 21]. Reminder
trials for TB have demonstrated benefits on adherence
to appointments [22]. Yet, treatment adherence and
completion rates remain suboptimal across high-risk
groups, and no intervention has shown consistent effect-
iveness [15]. For example, the role of education as a pre-
dictor of adherence has not been well-defined [15].
Similarly, the effect of immediate compared to deferred
monetary incentives on adherence has not been shown
to significantly differ [23].
Potential benefits of text messaging
Over two trillion text messages were sent in the USA in
2011, with more than 80% of the US population owning
a mobile phone and almost 70% of these phone owners
regularly sending or receiving text messages [24]. Unlike
the digital divide with online technologies, people of color
and low-income individuals are more likely to text [25].
With this widespread adoption, texting offers promise for
public health departments to make health information
more readily accessible. Texting allows quick, direct com-
munication that works on all types of mobile phones.
Texting can be used in conjunction with other initiatives
to establish and maintain contact between the patient and
provider over the course of treatment. The information-
motivation-behavioral skills model demonstrates that in-
formation is a prerequisite for good adherence, yet it is
not sufficient in itself in explaining behavior [26]. Mo-
bile phones can benefit both patients and providers by
overcoming resource limitations, structural barriers,
and behavioral limitations in providing motivation and
the development of desired behavioral responses [27].
Conceptually, text messaging relies on constructs from
the Social Cognitive Theory where positive outcome ex-
pectations, e.g., beliefs about the likelihood and value of
the consequences of taking medication, as well as self-
efficacy (beliefs about personal ability), substantially
contribute to forming an intention to perform a desired
action [28]. For example, participants in a multisite ran-
domized clinical trial of HIV-infected adults initiating
antiretroviral therapy asked to respond to a text mes-
sage indicating that they had taken their medications
were more likely to take their medications [29, 30].
Text messages have the advantage of being efficient
and are considerably less invasive to daily lives com-
pared to phone calls [31]. Mobility, instantaneous ac-
cess, and direct communication are likely to enhance
efficiency of service delivery [32, 33]. With increased ef-
ficiency, cost savings are substantial and include direct
costs defrayed to the health system as well as opportun-
ity costs of missed appointments and lengthy treatment
duration [34, 35].
A stronger evidence base needs to be developed
around the mobile health field for TB, before effective
approaches can be implemented and high-quality data
are lacking [36, 37]. Only recently have studies investi-
gated the effectiveness of texting reminders for active
tuberculosis treatment [34, 38, 39]. To our knowledge,
no studies have been completed and only one study is
currently being carried out in the context of latent TB
infection [40]. As such, tailoring a reminder system for
LTBI patients who self-administer medications could im-
prove adherence to LTBI treatment and provide evi-
dence for adopting or expanding reminder systems. A
commonly used practice for LTBI is a phone call to re-
mind patients to visit the clinic for a check-in and
monthly refill. Since we would like to assess the inde-
pendent effect of text messages on treatment adherence,
we propose to evaluate the use of daily text messaging,
in addition to the reminder phone call. We propose a
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study examining the feasibility of a randomized controlled
trial using text messages to improve LTBI treatment ad-
herence. This study will provide us the necessary data to
design a large randomized controlled trial which will
examine the effectiveness of text messaging.
Study objectives
We aim to determine the feasibility and acceptability of
text reminders for improving adherence in latent TB pa-
tients. Specific objectives of the current study are to (1)
assess the feasibility of the intervention as indicated by
participant recruitment and retention and (2) evaluate
the acceptability of the intervention, as indicated by
intervention adherence, outcome measurement rates,
and feedback from participants.
Data will be used to design a definitive trial which will
test the hypothesis that the intervention will improve
medication adherence, as measured through an increase
in treatment completion rates, and result in higher self-
reported medication adherence, fewer missed appoint-
ments and doses, and a shorter course of treatment.
Methods/design
Overview
This is a single-blinded randomized controlled parallel
trial to test the feasibility of using text messages to im-
prove LTBI treatment adherence. Randomization will be
performed with a 1:1 allocation. The project is funded
through the American Lung Association and is being led
by researchers at the University of Arizona with recruit-
ment and collaboration taking place at the Pima County
Health Department (PCHD) TB Control Program in
Tucson, AZ, USA. This manuscript adheres to the
SPIRIT checklist reporting guidelines (Additional file 1).
Participants
Forty participants from PCHD are being recruited, with
adequate representation expected from samples previ-
ously noted to fail treatment [13]. Pima County Health
Department prioritizes LTBI screening based on recent
contact to an infectious TB patient, migration from a
high-burden TB country, as well as the USPSTF guide-
lines [9]. Persons who are at least 18 years of age and
able to provide informed consent, agree to initiate LTBI
treatment, are prescribed self-administered 4-month ri-
fampin or 9-month isoniazid therapy, and have a phone
that can receive text messages, will be eligible for the
study. Participants will also need to be able to commu-
nicate via text messaging or have a family member or
friend able to provide assistance with messages for the
duration of the study. Patients are ineligible if they cur-
rently have active tuberculosis disease. Participants
from the pilot will not be included in a proposed larger
follow-up study.
Participant recruitment and consent
All participants will be recruited directly from the
PCHD Tuberculosis Control Program. A clinic nurse
will refer interested participants to study personnel, at
which point these personnel will assess eligibility and
obtain informed consent. The referral will occur when a
patient agrees to begin treatment for LTBI. Participants
will be informed through the consent process that they
may withdraw from the study at any time for any reason
without it affecting their medical care. Participants will
also be provided the purpose of the study, study objec-
tives, as well as how study success will be measured
[41]. The informed consent document will use simple
language to minimize barriers posed by low literacy. A
language line will also be used to verbally explain study
materials, assist with language difficulties, and overcome
reading difficulties. Family members or friends who are
present at the time of recruitment will also be utilized
for support and translation, but will not take the place
of the language line.
Eligible individuals will be recruited over a 12-month
period. Following consent, all participants will complete
baseline assessments and will be randomly allocated
to group.
Randomization and allocation
Eligible patients who have given informed consent and
completed baseline assessments will be randomly
assigned to receive either text messaging and usual care
or usual care only. A list allocating participants to the
intervention or control arm will be generated by the bio-
statistician (MB), who has no patient contact, using the
statistical software R. Randomized blocks of variable size
will be used to ensure balance between the arms. Block
size will be random to reduce predictability of the se-
quence. Each individual will be assigned a unique study
code, which will be used throughout the research study
in place of any identifying information. Participant iden-
tification and allocation will be placed in sealed opaque
envelopes. Allocation codes will be concealed until study
group is assigned. Participants will be identified to the
research team only by phone number and study code.
Blinding
Investigators will be masked to group allocation, but
participants and research staff will not, given their active
study roles.
Usual care
Standard of care for LTBI patients at this clinic includes
an initial discussion of medication risks, benefits, and
side effects. Treatment usually involves daily self-
administration of medication for a prolonged period of
therapy. Treatment typically involves taking rifampin
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600 mg daily for 4 months or isoniazid 300 mg daily for
9 months. If a patient agrees to treatment, they are given
a 30-day supply of medication. Subsequent follow-up
involves monthly clinic visits, at which time there is an
assessment of symptoms, side effects, and adherence;
blood-work is performed; and another month’s supply of
medication is provided. The usual practice of care with
regard to adherence is a phone reminder prior to the
next appointment.
Intervention
Text group participants will receive a daily text reminder
sent by an automatic messaging system in addition to
the standard of care. This automation will anonymize
messaging to all but the study coordinator, who sends
out the message. Participants will be asked optimal times
to receive daily texts and will receive texts in their lan-
guage of choice. Participants’ phone numbers will be en-
tered into a secured web platform to automatically send
text message reminders at pre-specified intervals. A de-
livery report function will be used to verify that mes-
sages were received and opened. The system meets the
key requirements of a highly functional texting system,
including customization, personalization, message notifi-
cation, and remote access [42]. The script sent to indi-
viduals will state “This is a reminder to take your
medication. Please respond.” The Platform for Research
Integrated Messaging (PRiM), a web-based software
suite developed at the University of Arizona, allows text
messaging integration and management of text messages.
It is hosted on secure servers, includes only de-identified
data and delivered as SaaS (Software as a Service). To the
user, text messages appear to come from a specific and
established phone number. Participants will use existing
mobile phone services; while phones and network airtime
will not be paid for, participants will be provided a $40
incentive, paid at the 2-month visit and at final survey
completion. Participants can request to opt out of the
intervention at any time by calling or texting “stop.”
Outcome measures
All outcomes will be assessed through in-person partici-
pant visits or collection from clinic records. Questionnaires
will be completed by trained interviewers who are blinded
to participant allocation.
The primary feasibility outcomes are summarized in
Table 1.
While this pilot study will not have the power to de-
tect differences in efficacy, efficacy outcomes will be
measured to test procedures for early indication of a
promising intervention. The primary efficacy outcome is
the difference in proportion of participants completing
treatment in each of the study groups. Successful treat-
ment completion is defined as taking at least 80% of the
doses of rifampin prescribed within 20 weeks [43]. Esti-
mates of treatment completion will be used to indicate
whether the treatment appears promising and to esti-
mate sample size for a future definitive trial. Additional
secondary outcomes include proportion of missed visits
out of total scheduled visits; the number and length of
delays in medication refill; number of missed doses;
overall length of treatment (time to dropout); and self-
reported adherence. While potentially overestimating
true adherence, self-reported adherence is a robust
measure of adherence [44, 45]. A brief pre-survey and
more detailed semi-structured interviews will be con-
ducted with all individuals to qualitatively assess prefer-
ences, attitudes, and satisfaction with the study, as well
as barriers to adherence.
The following assessments will be completed by par-
ticipants (Fig. 1), as per the SPIRIT Statement [46].
Sample size
The sample size of 40 will yield a 5% margin of error
(95% confidence interval half-width) of no greater than
7.7%, for any of the binary feasibility outcomes (recruit-






single binary proportion and the value of p which maxi-
mizes the standard error (p = 0.5). A sample size of n =
40 participants [47] is expected to provide data sufficient
to estimate variability in outcome measures as well as to
assess trial feasibility. Furthermore, Whitehead et al.
have shown that 40 participants in a pilot study are opti-
mal when the future main trial is expecting a small to
medium effect size [48]. We also expect qualitative data
to be saturated with 30 interviews, at which we expect
to yield sufficient data to achieve redundancy. However,
we will increase the sample size until saturation is
reached if needed [49].
Table 1 Feasibility outcomes
Outcome How assessed Target
Recruitment How many approached by clinic, how many referred, how many
study eligible, how many consented; why ineligible or refused;
how long to recruit each patient
40% recruitment rate, based on recruitment
of all eligible
Retention How many drop out at each monthly time point, who and why 70% retention rate
Patient satisfaction and
acceptability
Patient perceptions, satisfaction, and acceptance of the intervention
through pre- and post-surveys
75% satisfaction rate based on positive
responses to questionnaires
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Data collection, management, and analysis
Trained interviewers will collect socio-demographic infor-
mation and clinical data through in-person participant
visits or collection from clinic records for all participants,
including adherence rates (dose counts, appointments) at
baseline and then on a monthly basis. Additionally, infor-
mation will be collected at baseline regarding sharing of
phones, baseline perceptions of texting, and frequency of
texting. Per usual care, participants are expected to return
to clinic once a month for a check-in and medication re-
fill. Self-reported missed doses and pill bottle counts are
recorded in the medical chart and will be abstracted to a
study monitoring log. Figure 1 shows the various data ele-
ments collected at study time points and Fig. 2 a sample
visit protocol for the 4-month regimen.
Participants will be prospectively followed until treat-
ment completion or dropout. We will define participants
as lost to follow-up if they are unable to be traced per
Fig. 1 Schedule of enrolment, interventions, and assessments
Fig. 2 Sample visit protocol, 4-month regimen
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clinic protocol (two phone calls and a certified letter).
The research coordinator will maintain a log document-
ing refusals and reporting recruitment numbers.
Detailed semi-structured interviews will be conducted
with all individuals during their final visit to qualitatively
assess preferences, attitudes, and satisfaction with the
study intervention. User attitudes will be assessed for
both the texting intervention and phone reminder sys-
tem. Text group participants will be asked for reasons
for non-response. These might include forgetting to text
back, being too busy, personal reasons, or not under-
standing the protocol. Treatment defaulters, as assessed
through chart review, will be asked for non-adherence
reasons and satisfaction with various reminder systems
through a one-time phone interview. All interview
guides will have been piloted during staff training and
presented by an interviewer familiar with the language
or else with the aid of an interpreter service. Participants
will be asked whether messages are useful and accept-
able, whether they found the message text and format to
work, and are of preferred quantity, frequency, and tim-
ing of use. Information will also be collected to better
understand initial expectations and whether attitudes
had changed towards the intervention throughout the
process. In addition, they will be asked whether they
would like to keep using the text message reminders
after the study and whether they would recommend the
text message reminder system to others. We anticipate
including some redundancy of questions to assess internal
consistency of responses. We will also collect (a) demo-
graphic characteristics of participants, (b) perceived bene-
fits of, and barriers to, LTBI treatment completion, (c)
self-efficacy to complete treatment, (d) perceived suscepti-
bility to TB disease, (e) satisfaction with provider interac-
tions and patient education, and (f) preferred reminder
system, including whether phone sharing might have
affected the intervention and perceptions of costs.
Study data will be collected and managed using REDCap
(Research Electronic Data Capture) electronic data cap-
ture tools hosted at the University of Arizona’s College of
Medicine. REDCap is a secure, web-based application
designed to support data capture for research studies, pro-
viding (1) an intuitive interface for validated data entry;
(2) audit trails for tracking data manipulation and export
procedures; (3) automated export procedures for seamless
data downloads to common statistical packages; and (4)
procedures for importing data from external sources. All
data will be password-protected and de-identified [50].
Data will be entered at the time of collection, and clinic
data will be abstracted by the clinic coordinator and inte-
grated into the database. To facilitate analysis, the data-
base will include the ability to generate custom reports
exportable to other applications. Summary reporting of
data will be conducted monthly to ensure satisfactory data
quality. Regular meetings will be held with co-principal in-
vestigators to assess progress of data collection.
The database will also be used to capture lack of response
and number of approach attempts. Individual response
rates will be calculated as the number of user responses
divided by the total number of surveys sent out. All
data will be kept on secured servers. Questionnaires
will be administered in confidentiality and responses
kept in a secured office.
Statistical methods
Analyses regarding feasibility of the study will primarily
be descriptive in terms of recruitment and retention
rate, reasons for dropout, and deviations from protocol.
Participation bias will be assessed by comparing individ-
uals included in the study to study refusals as well as
broader clinic participant characteristics.
Qualitative data will be transcribed and analyzed for
patterns and themes using NVivo 10, a qualitative analysis
program with which a member of the team has substantial
experience [51, 52]. Answers to open-ended questions re-
garding barriers and benefits of the reminder systems will
be categorized and described.
We will compare the proportion of participants com-
pleting treatment in each of the study groups in order to
assess preliminary efficacy [43]. Results will be reported
as the number (%) of participants for each treatment
group, the risk difference, and 95% confidence intervals.
Secondary outcomes will include proportion of missed
visits out of total scheduled visits; the number and
length of delays in medication refill; number of missed
doses; overall length of treatment (time to dropout); and
self-reported adherence.
Rescheduled or canceled appointments will not be
considered as missed although rate of canceled or resched-
uled appointments will be collected. Comparisons of the
intervention group with the control group for all continu-
ous or count outcomes will be carried out using t tests.
Proportions will be compared using a non-continuity-
corrected test of proportions. Time to dropout will be
described using survival analysis methods.
Methods: monitoring
Data monitoring and harms
Due to the minimal risks of the study and nature of the
intervention, there is no formal Data Safety Monitoring
Board. On a monthly basis, the two study arms will be
compared for event rates, including side effects and their
severity, as well as distinguishing medication-related
from other side effects.
Auditing
All research staff have received human subjects re-
search training and will receive appropriate training in
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recruitment, data collection, and management. Ongoing
study progress will be tracked with regular monitoring
by the PI with study and clinic personnel, training of all
staffs involved in the process, monthly research team
meetings, and regular review to ensure that study tar-
gets are being met.
Confidentiality
The web management application (PRiM) is password-
protected, and data can be stored in encrypted format
when texting other subjects. Texts are addressed to de-
identify usernames, and pass through the website, thus
keeping identities private—other subject’s phone num-
bers are never seen by subjects—as all contacts are indir-
ect through the web application. Only HIPAA-trained
researchers are allowed to access or download the data
via the website.
Discussion
Treatment adherence and completion rates for latent tu-
berculosis infection remain suboptimal across high-risk
groups. This study is the first, to our knowledge, to as-
sess the feasibility and acceptability of text messaging as
an adjunct to usual care for treatment for LTBI in the
USA. Strengths of this study include an adequate re-
cruitment period, provision of an incentive that will help
balance concerns related to messaging costs, and in-
depth and ongoing collection of process measures.
Some limitations and challenges of this study are the
messaging cost for participants, the risk of participants
running out of plan minutes, and the possibility that
participants change numbers or service providers. Voice
calling and text messaging are equally affected by chan-
ging phone numbers, and text messaging might be ad-
vantageous if a patient is running low on plan minutes.
We will recommend that the clinic ask participants
about their phone plan at each visit. Participants may
miss appointments no matter the intervention, and we
recognize the possible limitations of self-reported adher-
ence, including the fact that reporting during the week
prior to an appointment may not reflect adherence pat-
terns over time, since participants may become more
adherent right before an appointment [53]. Finally, there
is possible selection bias of enrollees, since participants
must have a phone and be willing to text. Participants
may also need to be comfortable with the communication
style in order to effectively show behavior change [27].
We will compare our demographic and clinical data to
those of non-enrollees, in order to ensure generalizability
of our findings.
As a result of this pilot study, we will advance know-
ledge regarding best practices regarding adherence for
treatment of latent TB infection. As this is a pilot study, we
recommend results be interpreted with caution. Further
intervention studies should verify the results of this study
and scale up the proposed approach to broader popula-
tions and clinical sites.
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